CNTB

Company Overview — What Does Connect Biopharma Holdings Ltd Do?

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China. Connect Biopharma Holdings Ltd (CNTB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Zheng Wei and employs approximately 110 people. With a market capitalization of $152M, CNTB is one of the notable companies in the Healthcare sector.

Connect Biopharma Holdings Ltd (CNTB) Stock Rating — Hold (April 2026)

As of April 2026, Connect Biopharma Holdings Ltd receives a Hold rating with a composite score of 30.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.CNTB ranks #1,768 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Connect Biopharma Holdings Ltd ranks #179 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CNTB Stock Price and 52-Week Range

Connect Biopharma Holdings Ltd (CNTB) currently trades at $2.88. The stock gained $0.10 (3.6%) in the most recent trading session. The 52-week high for CNTB is $3.28, which means the stock is currently trading -12.2% from its annual peak. The 52-week low is $1.23, putting the stock 134.1% above its annual trough. Recent trading volume was 201K shares, suggesting relatively thin trading activity.

Is CNTB Overvalued or Undervalued? — Valuation Analysis

Connect Biopharma Holdings Ltd (CNTB) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.76x, versus the sector average of 2.75x. The price-to-sales ratio is 615.81x, compared to 1.66x for the average Healthcare stock.

At current multiples, Connect Biopharma Holdings Ltd trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Connect Biopharma Holdings Ltd Profitability — ROE, Margins, and Quality Score

Connect Biopharma Holdings Ltd (CNTB) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -528.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -395.8% versus the sector average of -33.1%.

On a margin basis, Connect Biopharma Holdings Ltd reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -90740.6% (sector: -66.1%). Net profit margin stands at -86687.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -98.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CNTB Debt, Balance Sheet, and Financial Health

Connect Biopharma Holdings Ltd has a debt-to-equity ratio of 34.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.74x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $38M.

CNTB has a beta of 0.12, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Connect Biopharma Holdings Ltd is 43/100, reflecting average volatility within the normal range for its sector.

Connect Biopharma Holdings Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, Connect Biopharma Holdings Ltd reported revenue of $64,000 and earnings per share (EPS) of $-1.00. Net income for the quarter was $-55M. Gross margin was 100.0%. Operating income came in at $-58M.

In FY 2025, Connect Biopharma Holdings Ltd reported revenue of $64,000 and earnings per share (EPS) of $-1.00. Net income for the quarter was $-55M. Revenue grew -99.8% year-over-year compared to FY 2024. Operating income came in at $-58M.

In Q3 2025, Connect Biopharma Holdings Ltd reported revenue of $16,000 and earnings per share (EPS) of $-0.31. Net income for the quarter was $-17M. Operating income came in at $-18M.

In Q2 2025, Connect Biopharma Holdings Ltd reported revenue of $48,000 and earnings per share (EPS) of $-0.23. Net income for the quarter was $-13M. Gross margin was 100.0%. Operating income came in at $-13M.

Over the past 8 quarters, Connect Biopharma Holdings Ltd has demonstrated a growth trajectory, with revenue expanding from $0 to $64,000. Investors analyzing CNTB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CNTB Dividend Yield and Income Analysis

Connect Biopharma Holdings Ltd (CNTB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CNTB Momentum and Technical Analysis Profile

Connect Biopharma Holdings Ltd (CNTB) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 25/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CNTB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Connect Biopharma Holdings Ltd (CNTB) ranks #179 out of 838 stocks based on the Blank Capital composite score. This places CNTB in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CNTB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CNTB vs S&P 500 (SPY) comparison to assess how Connect Biopharma Holdings Ltd stacks up against the broader market across all factor dimensions.

CNTB Next Earnings Date

No upcoming earnings date has been announced for Connect Biopharma Holdings Ltd (CNTB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CNTB? — Investment Thesis Summary

Connect Biopharma Holdings Ltd presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 15/100 indicates premium valuation.

In summary, Connect Biopharma Holdings Ltd (CNTB) earns a Hold rating with a composite score of 30.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CNTB stock.

Related Resources for CNTB Investors

Explore more research and tools: CNTB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CNTB head-to-head with peers: CNTB vs AZN, CNTB vs SLGL, CNTB vs VMD.